| Q34795807 | Acinetobacter baumannii: emergence of a successful pathogen |
| Q41870610 | Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae |
| Q41269719 | Activities of doripenem (S-4661) against drug-resistant clinical pathogens |
| Q42905476 | Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms |
| Q50978365 | Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study. |
| Q42934573 | Antimicrobial activity of doripenem against bacterial isolates from humans and animals |
| Q42786167 | Available carbapenems: Properties and differences |
| Q28286055 | Carbapenems |
| Q36960048 | Carbapenems in the USA: focus on doripenem |
| Q37030838 | Carbapenems: a potent class of antibiotics |
| Q42049594 | Characteristics of doripenem: a new broad-spectrum antibiotic |
| Q43190490 | Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. |
| Q35026526 | Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections |
| Q37637359 | Doripenem versus bacteria: an emerging battleground |
| Q37160369 | Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. |
| Q28298996 | Doripenem: a new carbapenem antibiotic |
| Q37263205 | Doripenem: a review of its use in the treatment of bacterial infections. |
| Q36286220 | Ertapenem: a review of its use in the treatment of bacterial infections |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q42099309 | Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem |
| Q36993524 | In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. |
| Q33836698 | In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis |
| Q40049619 | In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States |
| Q37974745 | In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli |
| Q39927085 | In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli |
| Q36894452 | Introduction: the challenge of multiresistance |
| Q39609100 | Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase |
| Q37382976 | Management of meningitis due to antibiotic-resistant Acinetobacter species |
| Q36894462 | Non-fermentative Gram-negative bacteria |
| Q43446878 | Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem |
| Q40354083 | Panel strain of Klebsiella pneumoniae for beta-lactam antibiotic evaluation: their phenotypic and genotypic characterization. |
| Q42772390 | Penetration of intact blood-brain barrier by doripenem |
| Q39599930 | Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model |
| Q45954223 | Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. |
| Q27657333 | Structural and Biochemical Characterization of the Interaction between KPC-2 β-Lactamase and β-Lactamase Inhibitor Protein, |
| Q34969565 | The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria |
| Q37555757 | The use of carbapenems in the treatment of serious infections |
| Q37704397 | Treatment of Acinetobacter infections |
| Q40282005 | WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases |